JNT517-301
The goal of this Phase 3, randomized study is to assess the safety, efficacy, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adults (18 years of age or older) with PKU. Participants will receive either JNT-517 or placebo and will be…
- Investigator
- Roberto T Zori
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
JNT517-501 Extension study
- Investigator
- Roberto T Zori
- Status
- Accepting Candidates
JNT517-201 Adolescent
The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be…
- Investigator
- Roberto T Zori
- Status
- Accepting Candidates
- Ages
- 12 Years - 17 Years
- Sexes
- All